Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

9

Phase 3 clinical trials (the last 8 of which have been successful)


We have run numerous large successful international Phase 3 clinical trials.


Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas including immunology, oncology, hematology, and dermatology.

Compound

VTAMA (Tapinarof)

Indication

Psoriasis

Modality

Topical

Company

Dermavant

Commercialization

Compound

VTAMA (Tapinarof)

Indication

Atopic Dermatitis

Modality

Topical

Company

Dermavant

Phase 3

Compound

Brepocitinib

Indication

Dermatomyositis

Modality

Small Molecule

Company

Priovant

Phase 3

Compound

Brepocitinib

Indication

Systemic Lupus Erythematosus

Modality

Small Molecule

Company

Priovant

Phase 2

Compound

Brepocitinib

Indication

Other Indications

Modality

Small Molecule

Company

Priovant

Phase 2

Compound

Batoclimab

Indication

Myasthenia Gravis

Modality

Biologic

Company

Immunovant

Phase 3

Compound

Batoclimab

Indication

Thyroid Eye Disease

Modality

Biologic

Company

Immunovant

Phase 2

Compound

Batoclimab

Indication

WAIHA

Modality

Biologic

Company

Immunovant

Phase 1

Compound

Batoclimab

Indication

CIDP

Modality

Biologic

Company

Immunovant

Phase 1

Compound

Batoclimab

Indication

Graves' Disease

Modality

Biologic

Company

Immunovant

Phase 1

Compound

IMVT-1402

Indication

Numerous Indications

Modality

Biologic

Company

Immunovant

Compound

Namilumab

Indication

Sarcoidosis

Modality

Biologic

Company

Kinevant

Phase 2

Compound

RVT-2001

Indication

Transfusion Dependent Anemia in Patients with Lower-Risk MDS

Modality

Small Molecule

Company

Hemavant

Phase 1

Compound

AVFT-2101

Indication

Solid Tumors

Modality

Biologic

Company

Affivant

Preclinical

About Us

Interested in learning more?

Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

Our Companies

Nimble, entrepreneurial Vants

Explore our diverse family of biopharmaceutical and health technology companies.